If You're Wearing This Popular Health Tool, Experts Say To Take The Readings With 'A Pinch Of Salt'
Continuous glucose monitors (CGMs), which are sometimes also known as blood sugar monitors, can be key for people with diabetes.
They help those with the condition to keep an eye on their blood sugar levels, potentially preventing them from getting dangerously high or low.
But in a site entry, the University of Bath (whose scientists were involved in a recent paper published in The American Journal of Clinical Nutrition) said: 'Originally designed to help people living with diabetes... these devices are now being used by the health-conscious to track how different foods affect their glucose levels.'
And according to the recent research, it may be doing healthy people more harm than good.
The researchers said that CGMs can often overestimate how much sugar is in a person's blood.
When participants drank a smoothie, the CGM overestimated the glucose it gave participants' blood by 30% compared to a blood prick test.
Whole fruit, like eating an apple, was classified by the CGM as a medium-glycemic index (GI, or blood-sugar 'spiking') or high-GI food, whereas blood prick tests found they were actually low-GI.
CGMs also inaccurately said that participants' blood sugars stayed elevated for nearly 400% above the threshold recommended by Diabetes UK, which could lead to unnecessary and even unsafe diet changes and stress.
'CGMs may be inaccurate because they measure glucose in the fluid surrounding your cells, not directly in your blood,' Professor Javier Gonzalez from the University of Bath, who was involved in the study said.
'This can lead to discrepancies due to factors like time delays, blood flow, and how glucose moves between different parts of the body.'
Dr Gonzalez said they're 'fantastic tools for people with diabetes because even if a measurement isn't perfectly accurate, it's still better than not having a measurement at all'.
But 'for healthy individuals, relying on CGMs could lead to unnecessary food restrictions or poor dietary choices'.
Writing for the expert-led site Science Media Centre, where professionals react to large or viral studies, Dr Adam Collins, associate professor of nutrition at the University of Surrey, said: 'The use and interpretation of CGM devices in healthy individuals should be undertaken with caution.'
'They certainly shouldn't be used as the sole basis for dietary changes, restrictions, or extreme lifestyle changes.'
Dr Nicola Guess, academic dietitian at the University of Oxford, said: 'The investigators found that CGMs overestimate glucose to a clinically-relevant degree in healthy people without prediabetes or diabetes. This means that people who have normal glucose may be led to believe they have prediabetes.
'This is one of a growing number of studies which demonstrate how cautious we need to be when interpreting CGM data from a person without diabetes.
'In this study, the CGM estimated the 'time out of range' as 4-fold higher compared to the capillary value. Other studies have found CGMs can also underestimate glucose (for example during exercise) and are particularly inaccurate when glucose concentration changes rapidly.
'Taken together, I would advise people without diabetes using CGMs to interpret the output with a pinch of salt.'
I'm A Gynae Health Expert, This Is Why You Get Butt Pain On Your Period
Apple Cider Vinegar: What Belle Gibson's Story Tells Us About Our Search For Alternative Health
8 'Micro-Habits' That Can Help You Live A Happier, Healthier Life
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Omada Health goes public at $23 per share, marking second digital health IPO in 2025
Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada — musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management. Omada began trading at $23 per share on the Nasdaq on Friday. By midday, Omada stock traded as high as $27 per share, up 43% since the first trade. The IPO was initially priced at $19 per share. The digital health platform has found its footing in the weight management space, though not by offering popular GLP-1 treatments. The company doesn't plan on doing so in the future either, CEO Sean Duffy told Yahoo Finance. Duffy said that's one reason why "the capital markets have, in many ways, asked us to come in" to the public markets. The company has differentiated itself and avoided the pitfalls of an ever-changing GLP-1 market, which was plagued early on by shortages and then disruption after the FDA removed GLP-1s from its shortage list, ending access to copycats of the popular drugs. Omada provides clinical guidance to patients once they leave their doctor's office. It's a concept Duffy and his co-founders realized was needed more than a decade ago, in 2011, when the weight loss market and technology were very different. When asked if Duffy regretted not going public during the pandemic when digital health was experiencing an investment boom, he said no, because the company had only begun expanding beyond diabetes into other care areas, including weight loss. "When you're becoming a public company, you want to make sure to have your proof points out there," Duffy said. "In retrospect, it was a great decision." But Omada does have the pandemic to thank for its growth, as it put a spotlight on digital health services. The company has grown its user base through partnerships with large companies that offer the services to employees. In addition, Omada is partnered with pharmacy benefit managers, including CVS (CVS) and Cigna (CI) — the latter of which is also an early investor through its ventures arm. Omada began its journey by serving the needs of diabetics, including a partnership with Abbott (ABT) and users of its Freestyle Libre continuous glucose monitoring (CGM) devices. It has since expanded to the GLP-1 market by providing the same guidance services, including meal kits and lifestyle change advice, to patients. Still, the company has yet to turn a profit in its 14-year existence. Duffy said the company's losses are decreasing over time, and revenue continues to grow year over year. 'We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis,' the company said in its S-1 filing. The company stated it incurred net losses of $67.5 million and $47.1 million in 2023 and 2024, respectively. In the first quarter ended March 31 of this year, Omada lost $9.4 million compared to a $19 million loss in the same period a year prior. 'We incurred net losses of $67.5 million and $47.1 million for the years ended December 31, 2023 and 2024, respectively, and $19.0 million and $9.4 million for the three months ended March 31, 2024 and 2025, respectively.' Duffy said he hopes new investors can help guide the company to become a leading platform addressing chronic disease. "It's just a neat moment in time, where the new shareholders that are coming in can help me, and help us, imagine a path ... to bend the curve of disease," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
Omada Health goes public at $23 per share, marking second digital health IPO in 2025
Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada — musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management. Omada began trading at $23 per share on the Nasdaq on Friday. By midday, Omada stock traded as high as $27 per share, up 43% since the first trade. The IPO was initially priced at $19 per share. The digital health platform has found its footing in the weight management space, though not by offering popular GLP-1 treatments. The company doesn't plan on doing so in the future either, CEO Sean Duffy told Yahoo Finance. Duffy said that's one reason why "the capital markets have, in many ways, asked us to come in" to the public markets. The company has differentiated itself and avoided the pitfalls of an ever-changing GLP-1 market, which was plagued early on by shortages and then disruption after the FDA removed GLP-1s from its shortage list, ending access to copycats of the popular drugs. Omada provides clinical guidance to patients once they leave their doctor's office. It's a concept Duffy and his co-founders realized was needed more than a decade ago, in 2011, when the weight loss market and technology were very different. When asked if Duffy regretted not going public during the pandemic when digital health was experiencing an investment boom, he said no, because the company had only begun expanding beyond diabetes into other care areas, including weight loss. "When you're becoming a public company, you want to make sure to have your proof points out there," Duffy said. "In retrospect, it was a great decision." But Omada does have the pandemic to thank for its growth, as it put a spotlight on digital health services. The company has grown its user base through partnerships with large companies that offer the services to employees. In addition, Omada is partnered with pharmacy benefit managers, including CVS (CVS) and Cigna (CI) — the latter of which is also an early investor through its ventures arm. Omada began its journey by serving the needs of diabetics, including a partnership with Abbott (ABT) and users of its Freestyle Libre continuous glucose monitoring (CGM) devices. It has since expanded to the GLP-1 market by providing the same guidance services, including meal kits and lifestyle change advice, to patients. Still, the company has yet to turn a profit in its 14-year existence. Duffy said the company's losses are decreasing over time, and revenue continues to grow year over year. 'We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis,' the company said in its S-1 filing. The company stated it incurred net losses of $67.5 million and $47.1 million in 2023 and 2024, respectively. In the first quarter ended March 31 of this year, Omada lost $9.4 million compared to a $19 million loss in the same period a year prior. 'We incurred net losses of $67.5 million and $47.1 million for the years ended December 31, 2023 and 2024, respectively, and $19.0 million and $9.4 million for the three months ended March 31, 2024 and 2025, respectively.' Duffy said he hopes new investors can help guide the company to become a leading platform addressing chronic disease. "It's just a neat moment in time, where the new shareholders that are coming in can help me, and help us, imagine a path ... to bend the curve of disease," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Former La Masia midfielder forced to retire at 23 due to heart condition
Former La Masia midfielder forced to retire at 23 due to heart condition Joan Gonzalez, once regarded as one of La Masia's most promising young midfielders, has been forced to retire from professional football at just 23 years of age, reports MARCA. The decision comes after doctors at Italian club Lecce discovered a congenital heart condition during routine preseason medical checks ahead of the 2024/25 season. Advertisement Sadly, the nature of the condition makes it impossible for Gonzalez to continue playing at the highest level. Since the diagnosis, Gonzalez has not played a single minute this season. Despite undergoing a year's worth of examinations and specialised tests, the outlook has not changed. Lecce president Saverio Sticchi Damiani confirmed the unfortunate news in a public statement, stating, 'We called him back after a year for a new check-up, which took place a few days ago, and the situation remains the same. 'So, with great regret, I must tell you that he will not receive a definitive medical clearance and will no longer be able to play football at a professional level.' A career filled with promise and passion Joan Gonzalez has been forced into retirement. (Photo by) Born in Barcelona and trained at clubs like Cornella, FC Barcelona, and Lecce's youth academy, Gonzalez made a name for himself as a physically strong and technically gifted pivot. Advertisement After switching from La Masia to Lecce in 2021, he steadily worked his way into the Italian side's first team. In Serie A, Gonzalez made 44 appearances. During this time, he scored two goals and assisted four more, establishing himself as a reliable and talented midfield option for Lecce. Although his career has been cut short far too early, Gonzalez leaves the game with his head held high. He overcame countless challenges to reach the top, and even though his professional journey ends here, his story will remain one of inspiration and perseverance for future young players coming through La Masia and beyond.